Curcumin for the Treatment of Glioblastoma.

Anticancer Res

SignPath Pharma, Inc., Quakertown PA, U.S.A.

Published: December 2015

Glioblastoma multiforme is a highly aggressive primary cancer of the brain associated with a poor prognosis. Modest increases in survival can sometimes be achieved with the use of temozolomide and radiation therapy after surgery, but second-line therapy after recurrence has a limited efficacy. Curcumin has demonstrated promising results against this form of cancer in experimental models. The reported activity of curcumin against cancer stem cells, a major cause of glioblastoma resistance to therapy, and its ability to augment the apoptotic effects of ceramides, suggest it would have a synergistic effect with cytotoxic chemotherapy agents currently used in second-line therapy, such as lomustine.

Download full-text PDF

Source

Publication Analysis

Top Keywords

second-line therapy
8
curcumin treatment
4
treatment glioblastoma
4
glioblastoma glioblastoma
4
glioblastoma multiforme
4
multiforme highly
4
highly aggressive
4
aggressive primary
4
primary cancer
4
cancer brain
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!